8-K
filed May 26, 2023, 7:59 PM ET
CIK 0000887247
M&A
confidence high
sentiment neutral
materiality 0.90
DMK PHARMACEUTICALS Corp: M&A transaction — Adamis closes merger with DMK Pharmaceuticals; Ebrahim Versi named CEO and Chair
DMK PHARMACEUTICALS Corp
- Merger completed May 25; DMK shareholders received 302,815 Adamis common shares and 1,941.2 Series E Preferred shares.
- Ebrahim Versi appointed CEO and Chair; David Marguglio stepped down as CEO, remains president and COO.
- Series E Preferred convertible at 1,000 common per share; 9.99% beneficial ownership limitation; Nasdaq issuance cap.
- Board changes: Marguglio and Williams resign; Versi and Jannine Versi appointed to board.
- DMK stock options assumed: 231,490 Adamis shares; Dr. Versi holds options for 102,885 shares.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
David J. Marguglio resigned as Director at DMK PHARMACEUTICALS Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
David J. Marguglio and Richard C. Williams resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jannine Versi was appointed as Director at DMK PHARMACEUTICALS Corp.
- Action
- appointed
- Role
- Director
Exact text from the filing
Ebrahim Versi and Jannine Versi were appointed to the Board to fill those vacancies
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ebrahim (Eboo) Versi was appointed as Chief Executive Officer and Chair of the Board at DMK PHARMACEUTICALS Corp.
- Action
- appointed
- Role
- Chief Executive Officer and Chair of the Board
Exact text from the filing
Ebrahim (Eboo) Versi, M.D., Ph.D., the co-founder and chief executive officer of DMK, was appointed as the chief executive officer of the Company and as Chair of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David J. Marguglio was appointed as President and Chief Operating Officer at DMK PHARMACEUTICALS Corp.
- Action
- resigned as chief executive officer and appointed as president and chief operating officer
- Role
- President and Chief Operating Officer
Exact text from the filing
David J. Marguglio resigned as chief executive officer of Adamis; he continues as president of Adamis and as corporate secretary and was also appointed as chief operating officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Richard C. Williams resigned as Director at DMK PHARMACEUTICALS Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
David J. Marguglio and Richard C. Williams resigned from the Company’s board of directors
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
DMK PHARMACEUTICALS Corp: Filed Certificate of Designation for Series E Convertible Preferred Stock, designating 15,000 shares as Series E Preferred (effective 2023-05-24).
- Change
- charter amendment
- Effective
- 2023-05-24
Exact text from the filing
On May 24, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, designating 15,000 shares out of the authorized but unissued shares of its preferred stock as Series E Preferred
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
DMK PHARMACEUTICALS Corp completed an acquisition involving DMK Pharmaceuticals Corporation (closed 2023-05-25).
- Action
- acquisition
- Counterparty
- DMK Pharmaceuticals Corporation
- Closing
- 2023-05-25
Exact text from the filing
On May 25, 2023, Adamis Pharmaceuticals Corporation, a Delaware corporation (“Adamis” or the “Company”), completed its merger transaction with DMK Pharmaceuticals Corporation (“DMK”)
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.